Sodium Valproate Versus Levetiracetam in Pediatric Generalized Epilepsy: A Comparative Study

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology

Background:

• Generalized epilepsy affects a significant number of children.
• Effective and safe anti-seizure medications (ASMs) are crucial for managing pediatric epilepsy.
• Newer ASMs offer potential improvements in treatment outcomes.

Purpose of the Study:

• To compare the efficacy, safety, and tolerability of sodium valproate (VPA) and levetiracetam (LEV) in pediatric patients with generalized epilepsy.

Main Methods:

• A prospective, randomized study involving 211 children (aged 2-14 years) with generalized seizures.
• Patients were randomized to receive either VPA or LEV for up to six months.
• Outcomes assessed included seizure-free duration, seizure-free rates, adverse events, tolerability, and compliance.

Main Results:

• Sodium valproate (VPA) showed a significantly longer seizure-free duration and higher seizure-free outcome rates at six months compared to levetiracetam (LEV).
• The VPA group required significantly shorter hospital stays.
• While VPA was associated with more nausea, vomiting, and weight gain, LEV had more behavioral adverse effects. Elevated SGPT was more common with VPA.

Conclusions:

• Sodium valproate (VPA) is more efficacious than levetiracetam (LEV) for seizure control in pediatric generalized epilepsy.
• Both VPA and LEV have specific safety profiles that need to be managed.
• Treatment decisions should balance efficacy with the distinct safety concerns of each ASM in children.